Sarah Lofgren is part of a team of researchers conducting a trial of hydroxychloroquine. Working out of the University of Minnesota, the team is providing the drug to first responders to assess the impact in preventing the onset of COVID-19 as well as the drug’s ability to mitigate the more severe symptoms of the disease.

In this episode, we discuss:

• The impact of anecdotal evidence of hydroxychloroquine’s usage around the world
• If pandemics offer an excuse to relax drug approval protocols
• Why use First Responders in a hydroxychloroquine trial
• If therapies like hydroxychloroquine provide enough breathing space to get America back to work